ATR and cancer: However, olaparib is in various phase 2 trials with the ATR inhibitor, AZD6738, for a variety of cancer types (NCT03682289, NCT03787680, NCT03462342, NCT04065269, NCT0387095, NCT04498021, NCT04090567, NCT02576444, NCT04417062, NCT03740893, NCT03579316, NCT03330847 and NCT02937818) and niraparib is in phase 1 trials in combination with various ATR inhibitors (NCT03682289, NCT03787680, NCT03462342, NCT04065269, NCT04170153, NCT04149145 and NCT04267939).